We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Anti-Heat Shock Protein 27 Antibody Levels and Diabetes Complications in the EURODIAB Study.
- Authors
Burt, Davina; Bruno, Graziella; Chaturvedi, Nish; Schalkwijk, Casper; Stehouwer, Coen D.; Witte, Daniel R.; Fuller, John H.; Pinach, Silvia; Perin, Paolo Cavallo; Gruden, Gabriella
- Abstract
OBJECTIVE -- To assess whether serum anti-heat shock protein 27 (HSP27) antibody levels are associated with micro- and macrovascular complications of type 1 diabetes. RESEARCH DESIGN AND METHODS-- Anti-HSP27 IgG antibody levels were measured in 531 type 1 diabetic subjects recruited as part of the cross-sectional analysis of the EURODIAB Prospective Complications Study. Case subjects (n = 363) were defined as individuals with one or more diabetes complications and control subjects (n = 168) as individuals with no evidence of any diabetes complication. RESULTS -- Anti-HSP27 levels were comparable in case and control subjects (19.6 arbitrary units/ml [11.3-32.7] vs. 20.4 arbitrary units/ml [11.7-35.3], geometric mean [interquartile range]), and there was no correlation between HSP27 and anti-HSP27 levels (r = 0.01, P = 0.81). In logistic regression analysis, anti-HSP27 was not associated with the presence of complications, even after adjustment for main risk factors. CONCLUSIONS -- Anti-HSP27 antibody levels are not a marker of vascular complications in type 1 diabetes.
- Subjects
IMMUNOGLOBULINS; HEAT shock proteins; DIABETES complications; DIABETIC angiopathies; IMMUNOGLOBULIN G
- Publication
Diabetes Care, 2009, Vol 32, Issue 7, p1269
- ISSN
0149-5992
- Publication type
Article
- DOI
10.2337/dc08-2271